US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redeye initiates coverage of A1M Pharma

We initiate coverage of A1M Pharma, a early stage biotech company developing a candidate to treat acute kidney injuries in associating with cardiac surgery. With a history of disappointment we now see real potential in A1M Pharma with their new management and strategy as they move towards meeting an unmet medical need. With a strong owner base and positive data from their first phase I study, we see a bright future ahead.  Read more and download the research update: http://bit.ly/2Nu00d0 Start following companies at Redeye to receive the latest equity research within Life Science and

A1M Pharma: ROSGard™ shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study

Preliminary data from the completed preclinical long-term study with an animal model clearly establish the strong protective effect against renal damage of the active substance in the candidate drug ROSGard™ in connection with radiation therapy. Clinical studies are scheduled to start in the beginning of 2018. The company's aim is to develop a pharmaceutical that will be administered in connection with each radiation therapy session in order to protect the kidneys and thereby enabling a more effective treatment.The molecular targeted therapy PRRT, which is mainly used as a treatment for

A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard™ and initiates GLP toxicology studies

A1M Pharma's manufacturing partner has successfully and completely within the set time frame manufactured the first large scale batch of the active substance in the candidate drug ROSGard™. After conducted tests that verified good quality and a high level of purity, A1M Pharma has decided to use this batch in the upcoming GLP toxicology studies.During 2016, A1M Pharma has performed an up-scaling of the manufacturing process for the active substance in the company's candidate drug ROSGard™, together with a leading European manufacturer. During 2016, the first large scale manufacturing of a

ROSGard™ shows renal protective effect during radiation therapy

A1M Pharma announces that the active substance in the company's candidate drug ROSGard™ shows a strong renal protective effect in connection with radiation therapy (PRRT) in a short-term preclinical study with an animal model. Results of the effect 6 months after treatment are expected by the end of Q1 2017.During the autumn of 2016, A1M Pharma chose kidney protection in connection with molecular targeted therapy to treat tumours (PRRT) as their first clinical application within acute kidney injury (AKI). PRRT is often used to treat aggressive endocrine cancer tumours in the

A1M Pharma has successfully conducted preclinical toxicology/safety studies within preeclampsia

A1M Pharma has successfully and according to plan conducted the first part of the company's toxicology/safety studies with the pharmaceutical compound in the company's candidate drug ROSGard™. In the studies, a maximum tolerated dose (MTD) has been established in two different animal models. These results will be used to establish the dosage levels to be used in the GLP-compliant toxicology studies.On the way towards clinical studies within treatment of preeclampsia, A1M Pharma is conducting several preclinical toxicology/safety studies. The first part, which aims to establish the maximum

A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injury

A1M Pharma – who develops and commercializes medical applications based on the endogenous protein A1M – has selected kidney protection in connection with radiation therapy for cancer (PRRT) as the first indication for their work within acute kidney injury (AKI). The aim is to be able to increase the radiation dose in order to fight the cancer more effectively.PRRT (Peptide Receptor Radionuclide Therapy) is a form of molecular targeted therapy which is used as treatment for cancer, commonly neuroendocrine tumours spreading quickly in the body in the gastrointestinal tract or the lungs in

A1M Pharma applies for trademark protection for ROSGard™ as the name of the company's candidate drug RMC-035

A1M Pharma has filed an application for trademark protection in Europe of the brand name ROSGard™ for the company's candidate drug RMC-035. Applications in other important markets will follow.The candidate drug in question is based on the endogenous protein A1M. The name refers to the potential to protect against harmful oxidative stress in the organs and other tissues. "ROSGard™ is an appropriate brand name that clearly associates our candidate drug with its mechanism of action. This enables us to be more precise in our communication with potential partners, investors and media and at

A1M Pharma to use experienced European CRO partner for preclinical toxicology studies

A1M Pharma has signed an agreement with Research Toxicology Centre, a leading European contract research organization with over 40 years of industry experience, as CRO partner for the company’s preclinical toxicology studies. The practical preparations for the studies have now been initiated, fully in accordance with the company’s development plan.In order to secure the best possible partner for the company’s toxicology studies within treatment of preeclampsia, A1M Pharma evaluated a number of European contract research organizations (CROs). The company decided on the Italian Research

A1M Pharma initiates research collaboration with global leader CSL Behring for combination treatment with A1M and plasma proteins

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential for combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.Many proteins in the human body contribute to immunoprotection against disease processes. Their different activities often act together to address

A1M Pharma finalizes drug candidate for treating pre-eclampsia and files for substance patent

A1M Pharma has developed a new drug candidate for treating pre-eclampsia based on a modified version of the natural protein alpha-1-microglobulin (A1M). Applications for substance patents have been filed in major geographical markets, significantly strengthening A1M Pharma’s intellectual property portfolio.A1M Pharma is developing a treatment and diagnostics for pre-eclampsia as well as a therapy for acute kidney injury based on the endogenous protein alpha-1-microglobulin (A1M). A1M occurs naturally in the body, and is an important component of the protective mechanism against the harmful

Report successful scientific advice meeting with Swedish Medical Products Agency regarding initial development program

In accordance with the previously communicated plan for development, A1M Pharma and the Swedish Medical Products Agency recently held a scientific advice meeting regarding the company’s drug development program. The meeting was held in preparation ahead of scaling up of drug manufacture and future clinical trials.A1M Pharma intends to maintain a continuous dialogue with the relevant regulatory authorities to ensure that the company’s development projects comply with demands placed by regulatory authorities. This first meeting with the Swedish Medical Products Agency focused on the design of

Research findings deepen the knowledge of A1M’s ability to neutralize toxic free hemoglobin

A scientific article published by scientists associated with A1M Pharma explains the process behind the protein A1M’s ability to neutralize free hemoglobin. The article has been approved for publishing in the scientific journal Biochim Biophys Acta (BBA) in January 2016 and is already available in their online version.A1M Pharma is developing treatment for pre-eclampsia and acute kidney injury, two indications where the damaging effects of free hemoglobin play a vital part. It is the so-called heme groups of the hemoglobin that can damage the cells in the body, and the article explains how

A1M Pharma initiates research collaboration with Fred Hutchinson Cancer Research Centre on the mechanisms of action of the protein A1M

A1M Pharma has signed a sponsored research collaboration agreement with the world-renowned Fred Hutchinson Cancer Research Centre in Seattle, USA, whose scientists include three Nobel laurates. The purpose of the collaboration is to elucidate molecular and tissue-specific mechanisms of action of the endogenous protein A1M.Within the frame of the collaboration, the internationally renowned nephrologist and researcher Dr Richard Zager of Fred Hutchinson Cancer Research Centre will be working closely with A1M scientists to broaden the knowledge of molecular and tissue-specific mechanisms of

Two new Swedish PhD thesis support scientific rationale for the treatment of oxidative stress with A1M protein

Two recently published PhD thesis from Lund University strengthen the scientific basis of the protein A1M's protective mechanism of action in connection with oxidative stress. Firstly, the potential of fetal hemoglobin and A1M as biomarkers of pre-eclampsia is verified in a larger patient group than previously and secondly A1M's therapeutic effects on oxidative stress is demonstrated for the first time in an animal model in the placenta and kidney and skin and eye cells.The first thesis, written by Ulrik Dolberg Anderson, under the supervision of A1M Pharma's co-founder, Professor Stefan

New publication highlights A1M protein’s role in regulating free hemoglobin

Scientists associated with A1M Pharma have published a scientific article that deepens the understanding of how free hemoglobin affects the function of the heart and the possibility to neutralize these effects with A1M, a protein that occurs naturally in the human body. The article was published on September 25 in the scientific journal Free Radical Biology and Medicine.This is the English version of a press release that was originally published in Swedish on October 7 2015, at 08:34 a.m. A1M Pharma is developing treatments for pre-eclampsia and acute kidney injury, two indications where

A1M Pharma appoints Let ‘em know to reach out to international trade press

A1M Pharma has initiated cooperation within international PR with Let ‘em know, a company specializing in helping Swedish life science companies to reach decision makers in the international life science industry with information about the company, its innovations and products. The PR activities will be conducted in close collaboration with Laika Consulting, A1M Pharma's partner for Investor relations communication.A1M Pharma focuses on the development of a treatment for preeclampsia and acute kidney injury, two indications with extensive medical needs globally. To engage Let ‘em know is a

Ex-Roche Martin Austin appointed Business Development Director of A1M Pharma

A1M Pharma has strengthened its management with the appointment of Martin Austin as Business Development Director. Martin Austin has 35 years of experience in the pharmaceutical industry, focusing on financing, strategy and business development. He has been a Board member of A1M Pharma since March 2015 and will take up his position with immediate effect.Martin joins as A1M Pharma maintains strong progress in its development projects focusing on diagnostics and treatment of pre-eclampsia, and treatment of acute kidney injury. The recruitment of Martin Austin, a global expert in financing,

A1M Pharma: Orphan Drug Designation granted in Europe for A1M Pharma’s treatment for preeclampsia

The European Commission has granted formal approval for A1M Pharma’s application for Orphan Drug Designation in Europe regarding the company’s treatment for preeclampsia.In May 2014, the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) announced its approval of A1M Pharma’s application for Orphan Drug Designation in Europe. This meant that COMP recommended the European Commission to grant formal Orphan Drug Designation, and the European Commission has now formally approved A1M Pharma’s application for Orphan Drug Designation for the treatment of preeclampsia.

There are no items matching the current filter
There are no more items matching the current filter
Back to top